Android app on Google Play

Arena Pharma (ARNA) Belviq Numbers Lowered at Needham & Company

April 11, 2014 6:35 AM EDT Send to a Friend
Get Alerts ARNA Hot Sheet
Price: $3.91 --0%

Rating Summary:
    4 Buy, 9 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 8 | New: 58
Trade ARNA Now!
Join SI Premium – FREE

Needham & Company analyst Alan Carr reiterated Hold rating and lowered estimates on Arena Pharma (NASDAQ: ARNA) ahead of Q1 earnings and spring review.

Carr comments, "Initiation of a direct to consumer (DTC) print campaign and expansion of the Eisai sales force appear to have had an impact on Belviq prescriptions in recent months. We believe a DTC television campaign planned for late April by Eisai may have an even greater effect. Broadly, however, we remain concerned by modest single-agent efficacy of Belviq and the risk of low patient retention."

The firm's new 1Q14 and 2014 U.S. Belviq sales estimates are $11.0M (was $11.5M) and $81.5M (was $91.5M). They project $3.5M (was $3.6M) in 1Q14 Belviq revenues to Arena. The firm also said its prescription refill assumptions have been too aggressive, however, and they are therefore lowering long-term Belviq sales estimates. Their 2015 estimate is $196.0M (was $259M).

For an analyst ratings summary and ratings history on Arena Pharma click here. For more ratings news on Arena Pharma click here.

Shares of Arena Pharma closed at $6.18 yesterday.





You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Needham & Company, Earnings

Add Your Comment